Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
Further demonstrates Honeywell's commitment to greenhouse gas reduction and support of customers' sustainability goals through innovative new products
This drug-device combination product is a metered-dose inhaler (MDI), which contains both budesonide (a corticosteroid that reduces inflammation) and formoterol (a long-acting bronchodilator that relaxes muscles in the airways to improve breathing)
New inhalers would have near-zero Global Warming Potential propellant
AstraZeneca will hold the registration and manufacture Pulmicort Respules, while Glenmark will commercialize the product in Columbia
The Institute of Pulmonology Medical Research & Development organised a symposium on early management of Covid-19
NPPA has capped the trade margin for Oxygen Concentrators at 70% on Price to Distributor (PTD) level
Subscribe To Our Newsletter & Stay Updated
